How do you beat Tesla, Google, Uber and the entire multi-trillion dollar automotive industry with massive brands like Toyota, General Motors, and Volkswagen to a full self-driving car? Just maybe, by finding a way to train your AI systems that is 100,000 times cheaper.
It’s called Deep Teaching.
Perhaps not surprisingly, it works by taking human effort out of the equation.
No industry will be spared.
The pharmaceutical business is perhaps the only industry on the planet, where to get the product from idea to market the company needs to spend about a decade, several billion dollars, and there is about 90% chance of failure. It is very different from the IT business, where only the paranoid survive but a business where executives need to plan decades ahead and execute. So when the revolution in artificial intelligence fueled by credible advances in deep learning hit in 2013–2014, the pharmaceutical industry executives got interested but did not immediately jump on the bandwagon. Many pharmaceutical companies started investing heavily in internal data science R&D but without a coordinated strategy it looked more like re-branding exercise with the many heads of data science, digital, and AI in one organization and often in one department. And while some of the pharmaceutical companies invested in AI startups no sizable acquisitions were made to date. Most discussions with AI startups started with “show me a clinical asset in Phase III where you identified a target and generated a molecule using AI?” or “how are you different from a myriad of other AI startups?” often coming from the newly-minted heads of data science strategy who, in theory, need to know the market.
However, some of the pharmaceutical companies managed to demonstrate very impressive results in the individual segments of drug discovery and development. For example, around 2018 AstraZeneca started publishing in generative chemistry and by 2019 published several impressive papers that were noticed by the community. Several other pharmaceutical companies demonstrated impressive internal modules and Eli Lilly built an impressive AI-powered robotics lab in cooperation with a startup.
However, it was not possible to get a comprehensive overview and comparison of the major pharmaceutical companies that claimed to be doing AI research and utilizing big data in preclinical and clinical development until now. On June 15th, one article titled “The upside of being a digital pharma player” got accepted and quietly went online in a reputable peer-reviewed industry journal Drug Discovery Today. I got notified about the article by Google Scholar because it referenced several of our papers. I was about to discard the article as just another industry perspective but then I looked at the author list and saw a group of heavy-hitting academics, industry executives, and consultants: Alexander Schuhmacher from Reutlingen University, Alexander Gatto from Sony, Markus Hinder from Novartis, Michael Kuss from PricewaterhouseCoopers, and Oliver Gassmann from University of St. Gallen.
The 400 kilogram wheeled system moves about the lab guided by LIDAR laser scanners and has an industrial robotic arm made by German firm Kuka that it uses to carry out tasks like weighing out solids, dispensing liquids, removing air from the vessel, and interacting with other pieces of equipment.
In a paper in Nature, the team describes how they put the device to work trying to find catalysts that speed up reactions that use light to split water into hydrogen and oxygen. To do this, the robot used a search algorithm to decide how to combine a variety of different chemicals and updated its plans based on the results of previous experiments.
The robot carried out 688 experiments over 8 days, working for 172 out of 192 hours, and at the end it had found a catalyst that produced hydrogen 6 times faster than the one it started out with.
A new study offers a better understanding of the hidden network of underground electrical signals being transmitted from plant to plant – a network that has previously been shown to use the Mycorrhizal fungi in soil as a sort of electrical circuit.
Through a combination of physical experiments and mathematical models based on differential equations, researchers explored how this electrical signalling works, though it’s not clear yet exactly what messages plants might want to transmit to each other.
The work builds on previous experiments by the same team looking at how this subterranean messaging service functions, using electrical stimulation as a way of testing how signals are carried even when plants aren’t in the same soil.
A new approach to designing motion plans for multiple robots grows “trees” in the search space to solve complex problems in a fraction of the time.
In one of the more memorable scenes from the 2002 blockbuster film Minority Report, Tom Cruise is forced to hide from a swarm of spider-like robots scouring a towering apartment complex. While most viewers are likely transfixed by the small, agile bloodhound replacements, a computer engineer might marvel instead at their elegant control system.
In a building several stories tall with numerous rooms, hundreds of obstacles and thousands of places to inspect, the several dozen robots move as one cohesive unit. They spread out in a search pattern to thoroughly check the entire building while simultaneously splitting tasks so as to not waste time doubling back on their own paths or re-checking places other robots have already visited.
A few scant equations can explain a variety of phenomena in our universe, over vast gulfs of space and time. Here’s a taste of just how powerful modern physics can be.
Neurons, specialized cells that transmit nerve impulses, have long been known to be a vital element for the functioning of the human brain. Over the past century, however, neuroscience research has given rise to the false belief that neurons are the only cells that can process and learn information. This misconception or ‘neurocomputing dogma’ is far from true.
An astrocyte is a different type of brain cell that has recently been found to do a lot more than merely fill up spaces between neurons, as researchers believed for over a century. Studies are finding that these cells also play key roles in brain functions, including learning and central pattern generation (CPG), which is the basis for critical rhythmic behaviors such as breathing and walking.
Although astrocytes are now known to underlie numerous brain functions, most existing computer systems inspired by the human brain only target the structure and function of neurons. Aware of this gap in existing literature, researchers at Rutgers University are developing brain-inspired algorithms that also account for and replicate the functions of astrocytes. In a paper pre-published on arXiv and set to be presented at the ICONS 2020 Conference in July, they introduce a neuromorphic central pattern generator (CPG) modulated by artificial astrocytes that successfully entrained several rhythmic walking behaviors in their in-house robots.
Dimensionality reduction is an unsupervised learning technique.
Nevertheless, it can be used as a data transform pre-processing step for machine learning algorithms on classification and regression predictive modeling datasets with supervised learning algorithms.
There are many dimensionality reduction algorithms to choose from and no single best algorithm for all cases. Instead, it is a good idea to explore a range of dimensionality reduction algorithms and different configurations for each algorithm.